基线[18F]FDG PET特征与大B细胞淋巴瘤CAR-T细胞治疗患者的生存和毒性相关
本研究回顾性纳入两家大学医院的56例接受CAR-T细胞治疗的大B细胞淋巴瘤患者,于输注前行[18F]FDG-PET,评估sDmax、TMTV、SUVmax及健康淋巴器官和肝脏摄取与预后及不良事件的关系。多因素分析显示TMTV(界值36 mL)是PFS的独立预后因素,sDmax(界值0.15 m-1)是OS的独立预后因素;CRP>35 mg/L和肝脏SUVmean>2.5与2-4级CRS相关,脾脏SUVmean>1.9与2-4级ICANS相关。
要点
- TMTV(界值36 mL)是PFS的独立预后因素(p<0.001)。
- sDmax(界值0.15 m-1)是OS的独立预后因素(p=0.008)。
- 肝脏SUVmean>2.5和CRP>35 mg/L与2-4级CRS相关,脾脏SUVmean>1.9与2-4级ICANS相关。
核心结论
- TMTV和sDmax分别对PFS和OS具有独立预后价值。
- 肝脏和脾脏平均摄取分别与2-4级CRS和ICANS的发生相关。
- 将这些生物标志物整合入临床工作流程可能有助于早期调整患者管理。
研究设计与样本
- 回顾性研究,从两家不同的大学医院纳入56例接受CAR-T细胞治疗的大B细胞淋巴瘤患者。
- 患者在CAR-T细胞输注前接受[18F]FDG-PET检查,病灶以最大摄取的41%为阈值半自动分割。
- 收集体征、sDmax、总代谢肿瘤体积(TMTV)、SUVmax以及健康淋巴器官和肝脏摄取强度,采用Kaplan-Meier法估计PFS和OS,并报告不良事件发生情况。
主要发现
- 中位随访9.7个月。
- 多因素分析显示TMTV(界值36 mL)是PFS的独立预后因素(p<0.001)。
- 多因素分析显示sDmax(界值0.15 m-1)是OS的独立预后因素(p=0.008)。
- CAR-T细胞治疗前C反应蛋白>35 mg/L(p=0.006)和肝脏SUVmean>2.5(p=0.027)与2-4级细胞因子释放综合征(CRS)相关。
- 脾脏SUVmean>1.9与2-4级免疫效应细胞相关神经毒性综合征(ICANS)相关。
关键数值与推荐
- TMTV界值36 mL,为PFS的独立预后因素(p<0.001)。
- sDmax界值0.15 m-1,为OS的独立预后因素(p=0.008)。
- C反应蛋白>35 mg/L(p=0.006)和肝脏SUVmean>2.5(p=0.027)与2-4级CRS相关。
- 脾脏SUVmean>1.9与2-4级ICANS相关。
临床怎么用
- 原文结论指出,将这些生物标志物整合入临床工作流程可能有助于早期调整患者管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chimeric antigen receptor (CAR) T cells have established themselves as an effective treatment for refractory or relapsed large B cell lymphoma (LBCL). Recently, the sDmax, which corresponds to the distance separating the two farthest lesions standardized by the patient's body surface area, has appeared as a prognostic factor in LBCL. This study aimed to identify [18F]FDG-PET biomarkers associated with prognosis and predictive of adverse events in patients treated with CAR T cells. METHODS: Patients were retrospectively included from two different university hospitals. They were being treated with CAR T cells for LBCL and underwent [18F]FDG-PET just before CAR T cell infusion. Lesions were segmented semi-automatically with a threshold of 41% of the maximal uptake. In addition to clinico-biological features, sDmax, total metabolic tumor volume (TMTV), SUVmax, and uptake intensity of healthy lymphoid organs and liver were collected. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The occurrence of adverse events, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), was reported. RESULTS: Fifty-six patients were included. The median follow-up was 9.7 months. Multivariate analysis showed that TMTV (cut-off of 36 mL) was an independent prognostic factor for PFS (p < 0.001) and that sDmax (cut-off of 0.15 m-1) was an independent prognostic factor for OS (p = 0.008). Concerning the occurrence of adverse events, a C-reactive protein level > 35 mg/L (p = 0.006) and a liver SUVmean > 2.5 (p = 0.027) before CAR T cells were associated with grade 2 to 4 CRS and a spleen SUVmean > 1.9 with grade 2 to 4 ICANS. CONCLUSION: TMTV and sDmax had independent prognostic values, respectively, on PFS and OS. Regarding adverse events, the mean liver and spleen uptakes were associated with the occurrence of grade 2 to 4 CRS and ICANS, respectively. Integrating these biomarkers into the clinical workflow could be useful for early adaptation of patients management.
引用
- Marchal E, Palard-Novello X, Lhomme F, et al. Baseline [18F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2023. PMID: 37721580. doi:10.1007/s00259-023-06427-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。